Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000557366 | SCV000655874 | uncertain significance | Combined oxidative phosphorylation defect type 27 | 2022-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 188 of the CARS2 protein (p.Thr188Met). This variant is present in population databases (rs142034206, gnomAD 0.05%). This missense change has been observed in individual(s) with epilepsy and intellectual disability (PMID: 30139652). ClinVar contains an entry for this variant (Variation ID: 475631). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV001266184 | SCV001444356 | uncertain significance | Inborn genetic diseases | 2018-11-19 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000557366 | SCV001524880 | uncertain significance | Combined oxidative phosphorylation defect type 27 | 2020-03-13 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Fulgent Genetics, |
RCV000557366 | SCV002791794 | uncertain significance | Combined oxidative phosphorylation defect type 27 | 2021-09-16 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000557366 | SCV003830590 | uncertain significance | Combined oxidative phosphorylation defect type 27 | 2019-11-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003403337 | SCV004122420 | uncertain significance | not specified | 2023-10-30 | criteria provided, single submitter | clinical testing | Variant summary: CARS2 c.563C>T (p.Thr188Met) results in a non-conservative amino acid change located in the tRNA synthetases class I, catalytic domain (IPR032678) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00029 in 241100 control chromosomes (gnomAD). c.563C>T has been reported in the literature in individuals affected with Alpers-Huttenlocher syndrome (Samanta_2018, Almubarak_2022). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 36360262, 34690748, 34426522, 30139652). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Mayo Clinic Laboratories, |
RCV004791568 | SCV005409652 | uncertain significance | not provided | 2024-01-16 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000557366 | SCV002106391 | pathogenic | Combined oxidative phosphorylation defect type 27 | 2022-03-17 | no assertion criteria provided | literature only |